Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, April 22, 2018 · 443,368,727 Articles · 3+ Million Readers

Rhino-Conjunctivitis - Disease Assessment and Therapeutics Analysis Forecasts to 2024

Rhino-Conjunctivitis 

PUNE, MAHARASHTRA, INDIA, February 26, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Rhino-Conjunctivitis - Pipeline Review, H2 2017”

Rhino-Conjunctivitis 

Overview

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2740084-rhino-conjunctivitis-pipeline-review-h2-2017

Major Key Players:

Astellas Pharma Inc

Bial - Portela & Ca SA

Faes Farma SA

Griffin Discoveries BV

HAL Allergy BV

Laboratorios LETI SL

Oxagen Ltd

 

Major Highlight

Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 9, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Rhino-Conjunctivitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. 

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2740084-rhino-conjunctivitis-pipeline-review-h2-2017

 

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire